Press Releases Year: - Any -201920182017201620152014 Items per page 102550 Date Title and Summary Additional Formats Toggle SummaryJan 08, 2018 Alder Announces $250 Million Committed Equity Financing View HTML Toggle SummaryJan 08, 2018 Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints in Pivotal PROMISE 2 Phase 3 Trial for Chronic Migraine Prevention View HTML Toggle SummaryMay 06, 2015 Alder Announces Presentations at 17th Congress of the International Headache Society on Data from ALD403 Clinical Trials View HTML Alder Announces Presentations at 17th Congress of the International Headache Society on Data from ALD403 Clinical Trials 15.1 KB Toggle SummaryJun 02, 2016 Alder Announces Presentations at Annual Meeting of the American Headache Society Supporting Development of ALD403 for Migraine Prevention View HTML Alder Announces Presentations at Annual Meeting of the American Headache Society Supporting Development of ALD403 for Migraine Prevention 19.4 KB Toggle SummarySep 08, 2016 Alder Announces Presentations at the European Headache and Migraine Trust International Congress Supporting Development of ALD403 for Migraine Prevention View HTML Alder Announces Presentations at the European Headache and Migraine Trust International Congress Supporting Development of ALD403 for Migraine Prevention 16.1 KB Toggle SummaryJun 27, 2014 Alder BioPharmaceuticals Added to Russell 3000(R) Index View HTML Alder BioPharmaceuticals Added to Russell 3000(R) Index 14.5 KB Toggle SummaryDec 16, 2014 Alder BioPharmaceuticals Announces Addition to NASDAQ Biotechnology Index View HTML Alder BioPharmaceuticals Announces Addition to NASDAQ Biotechnology Index 15 KB Toggle SummaryJul 18, 2017 Alder BioPharmaceuticals Announces Closing of Public Offering of Common Stock View HTML Alder BioPharmaceuticals Announces Closing of Public Offering of Common Stock 13.8 KB Toggle SummaryApr 12, 2016 Alder BioPharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares View HTML Alder BioPharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares 12.8 KB Toggle SummaryJan 05, 2015 Alder BioPharmaceuticals Announces Commencement of Follow-On Offering View HTML Alder BioPharmaceuticals Announces Commencement of Follow-On Offering 11.2 KB Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
Alder Announces Presentations at 17th Congress of the International Headache Society on Data from ALD403 Clinical Trials 15.1 KB
Alder Announces Presentations at Annual Meeting of the American Headache Society Supporting Development of ALD403 for Migraine Prevention 19.4 KB
Alder Announces Presentations at the European Headache and Migraine Trust International Congress Supporting Development of ALD403 for Migraine Prevention 16.1 KB
Alder BioPharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares 12.8 KB
